![]() |
Volumn 49, Issue SUPPL. 1, 2005, Pages
|
Chemotherapy for malignant mesothelioma
|
Author keywords
[No Author keywords available]
|
Indexed keywords
5,6 DIHYDROAZACITIDINE;
ALKYLATING AGENT;
ALPHA INTERFERON;
ANTHRACYCLINE ANTIBIOTIC AGENT;
ANTIMETABOLITE;
ANTINEOPLASTIC AGENT;
AZACITIDINE;
BLEOMYCIN;
CARBOPLATIN;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DACARBAZINE;
DETORUBICIN;
DIDEAZAFOLIC ACID;
DOXORUBICIN;
EDATREXATE;
EPIRUBICIN;
ETOPOSIDE;
FLUORODEOXYGLUCOSE;
FLUOROURACIL;
FOLIC ACID ANTAGONIST;
FOLINIC ACID;
GAMMA INTERFERON;
GEMCITABINE;
IFOSFAMIDE;
INTERLEUKIN 2;
IRINOTECAN;
MENOGARIL;
METHOTREXATE;
MITOMYCIN;
MITOMYCIN C;
MITOXANTRONE;
NAVELBINE;
OXALIPLATIN;
PEMETREXED;
PIRARUBICIN;
PLATINUM DERIVATIVE;
RALTITREXED;
TRIMETREXATE;
UNCLASSIFIED DRUG;
VINBLASTINE;
ZORUBICIN;
BLOOD TOXICITY;
CANCER CHEMOTHERAPY;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
DRUG SAFETY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MALIGNANT MESOTHELIOMA;
NEPHROTOXICITY;
OTOTOXICITY;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
SHORT SURVEY;
SIDE EFFECT;
SURVIVAL TIME;
|
EID: 20444394389
PISSN: 01695002
EISSN: None
Source Type: Journal
DOI: 10.1016/j.lungcan.2005.03.013 Document Type: Article |
Times cited : (9)
|
References (6)
|